Hepatocellular Carcinoma SITC CPG Mini Module - Immuno-Oncology Combination Therapy (IO-IO Therapy) in Second-Line Treatment of HCC

The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

Aiwu Ruth He, MD, PhD - MedStar Georgetown University Hospital, presents a case study on the use of nivolumab and ipilumumab as second-line treatment of advanced HCC.  Results from the CheckMate 040 clinical trial that led to FDA approval of this IO-IO therapy are also discussed.  Dr. He also presents information on the management of immune-mediated adverse effects and current knowledge gaps in the second-line treatment of HCC.   This mini module ends with a panel discussion on discontinuing immunotherapy in patients who respond to treatment. 

Run time: 19 minutes 46 seconds

Target Audience 

Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

SITC Online Education Disclaimer 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021). 
 
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.